The TCGA ovarian cancer database shows that about 10% of patients respond poorly to platinum-based chemotherapy, with tumors relapsing in seven months or ...
The TCGA database of serous ovarian carcinomas shows that ~10% of patients respond poorly to platinum-based chemotherapy, with tumors relapsing in seven months ...
Mar 21, 2016 · Ovarian cancer is the fifth leading cause of death among female cancers. Front-line therapy for ovarian cancer is platinum-based chemotherapy.
Mar 21, 2016 · Another 10% or so enjoy disease-free survival of three years or more. The objective of the present research is to identify a small number of ...
Abstract—The TCGA ovarian cancer database shows that about 10% of patients respond poorly to platinum-based chemotherapy, with tumors relapsing in seven ...
The TCGA ovarian cancer database shows that about 10% of patients respond poorly to platinum-based chemotherapy, with tumors relapsing in seven months or ...
Dive into the research topics of 'Optimized prediction of extreme treatment outcomes in ovarian cancer'. Together they form a unique fingerprint. Sort by ...
People also ask
What is the latest breakthrough in ovarian cancer treatment?
What is the breakthrough of ovarian cancer in 2024?
Are ovarian cancer treatments improving?
What is the most successful treatment for ovarian cancer?
Abstract. Ovarian cancer is the fifth leading cause of death among female cancers. Front-line therapy for ovarian cancer is platinum-based chemotherapy.
The RF models can effectively predict adnexal lesions, promising to be adjuncts to the preoperative prediction of ovarian cancer.
6 days ago · Bevacizumab, an anti-angiogenic medication, has demonstrated potential in enhancing progression-free survival (PFS) in EOC patients.